Ann: Acrux's fifth generic dossier accepted by FDA for review, page-19

Got it. That's a very fair assessment, I think. But what evidence is there to suggest they will get even somewhat close? Even in 2017, a blockbuster year for revenue ($23m I think it was), ACR made a loss. These days of course revenue is vastly lower; ex govt subsidies it was $2m (!!!!) last year. ACR has no products on the cusp of a strong ramp-up. Even approved products take a year or two to start generating revenue (which isn't necessarily a criticism of ACR; it's more just a reality of the entire process). And milestone payments, even if they get a few of them, won't be anywhere near sufficient to offset the $10m+ pa cash burn run rate. Delighted to hear a counterpoint; right now I don't see one.